Clinical Trial

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Study acronym: RISE 2
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Protocol Amendment History 77 amendments
This ClinicalTrials.gov record has been amended 77 times since 2023-11-10; most recent amendment 2026-04-30.
Status change: Not Yet Recruiting → Recruiting 2024-03-08
Trial Details
NCT Number NCT06132893
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions Focal Epilepsy
Enrollment 390 participants
Start Date 2024-03-14
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-01